MicroRNA Dysregulation in Colon Cancer Microenvironment Interactions: The Importance of Small Things in Metastases

MicroRNAs (miRNAs) are ~22-nt small noncoding RNAs that are processed from larger (80-nt) precursor hairpins by the RNase III enzyme Dicer into miRNA:miRNA duplexes. One strand of these duplexes associates with the RNAinduced silencing complex (RISC), whereas the other is generally degraded. The miRNA–RISC complex targets messenger RNAs triggering either translational repression or mRNA degradation [25]. The total number of miRNAs that are encoded in the human genome remains to be clarified. Initial estimates suggested there were up to 255 human miRNAs, but cloning and bioinformatic analyses have demonstrated that there are numerous nonconserved human miRNAs and suggest this number may be significantly larger [26]. Thousands of mammalian messenger RNAs are under selective pressure to maintain nucleotide sites matching microRNAs. Usually conserved targets are often highly expressed at developmental stages, before miRNAs expression and their levels tend to fall as the miRNA that targets them begins to accumulate. The phenomenon of the selective avoidance extended to thousand of genes enables temporal and tissue specific miRNA expression pattern, playing an important role in developmental timing [27]. It seems that the acquired differentiation and specialization is profoundly influenced by the impact of microRNA on mRNA repression and evolution. Overall, in a well differentiated tissue miRNAs are destabilizing many target messages to define tissue-specific transcript profile, but other targets could be modulated at translational level, without mRNA degradation. In that regard, changes of microenvironmental factors (as seen during cancer development) could accurately modulate protein expression patterns, acting on miRNA expression. A primary consequence in the transition from differentiated normal to de-differentiated neoplastic cell is the down modulation of miRNAs, involved in tissue specific differentiation. In humans, aberrant expression of miRNAs contributes to carcinogenesis by promoting the expression of proto-oncogenes or by inhibiting the expression of tumor suppressor genes. Such oncomirs have been demonstrated in a variety of haematological and solid tumors [28] and they contribute to cancer development and progression [20‐22]. Recently, the altered miRNAs expression in colon cancer has been reported (Table 1). However, the role that miRNAs play in the development of metastasis is more poorly defined [29]. It is worth of note that the same miRNAs could exert tumor suppressor or oncogenic effects, depending on the tumoral context and the stage of neoplastic disease. Recently, Arndt et al. [67] have shown that the re-expression of miR-143 or miR-145 leads to tumor suppressor and oncogenic phenotypes respectively, in a metastatic CRC model. In particular miR-145, reported as a ‘tumor suppressor’ in a non-metastatic context, showed oncogenic effects associated with the down-regulation of the G1/S cell cycle checkpoint and neuregulin pathways in the CRC metastatic setting.

The cancer microenvironment could contribute to miRNAs dysregulation affecting the epigenetic mechanisms (such as DNA methylation or histone acetylation) that regulate miRNA expression or influencing the maturation process of microRNAs [23, 24, 30].

As previously reported [31], DNA repair failure and cell survival represent the first step in colon cancer expansion. The pro-inflammatory cytokine IL-6 seems to play a role in the inactivation of DNA repair mechanisms and Bax-dependent apoptosis. Although data on the relationship between IL-6 production and tumor progression are still conflicting, recent studies suggest a pathogenetic function of the complexes formed between IL-6 and its soluble receptor (sIL-6R), in colon carcinoma. It seems that an increased formation of IL-6-sIL-6R complexes, able to interact with gp130 on the cell membrane (trans-signaling), leads to an increased expression and nuclear translocation of STAT3, which can cause the induction of anti-apoptotic genes, such as the Bax antagonist Bcl-xL protein [10, 32, 33]. Moreover, it has been observed that in critical conditions (hypoxia, glucose deprivation, oxidative stress), the activation of STAT3, together with increased levels of HIF1α (triggered by the hypoxic condition, 1% pO2) influences the preferential expression of VEGF-A165a isoform [17, 18, 33], that could lead to the inhibition of programmed cell death inducing anti-apoptotic Bcl-2 protein. Two different splicing isoforms of VEGF165 have been identified, exerting pro- or antiangiogenic actions respectively and whose formation is strictly controlled by micro-environmental factors [34]. The production of pro- or anti angiogenic forms of VEGF depends upon splice site choice in the C-terminal. Proxymal splice site selection in exon 8 generates pro-angiogenic isoforms such as VEGF-A165a, and distal splice site selection results in the antagonistic anti-angiogenic isoforms the VEGF-A165b. Cellular choice on splice site selection, strongly influenced by microenviromental factors, depends upon the activity of RNA-binding splice factors, such as ASF/SF2. Recent studies showed a nuclear and cytoplasmic localization of ASF/SF2 splicing factor and correlated the cytoplasmic localization to the inhibition of the proangiogenic form and to a strong increase of the anti-angiogenic isoform b [34, 35].

In colon cancer, it seems reasonable that the cooperative interaction between IL-6 and increased levels of HIF1α favours the shift versus the VEGF-A165 pro-angiogenic isoforms, all these factors contributing ultimately to tumor cell proliferation, apoptotic escaping and cell migration. Along these lines, we found an increase of IL-6 protein levels in human colon cancer tissues and the increase was positively correlated with the tumor stage [36]. IL-6, released as by the tumor itself as by tumor associated macrophages (TAMs), together with IL-6-induced VEGF-A, could influence tumor cell survival interfering with the Ku-CLU-Bax physical interactions. In a colon cancer progression model, we had previously demonstrated that IL-6 increased the expression of s-Clusterin (sCLU), a multifaceted protein strongly involved in cell survival, apoptosis escaping and metastasis [36‐39]. In vitro experiments have showed that the Ku-CLU-Bax interactions are modulated by IL-6, and IL-6 together with VEGF-A165 inhibit Bax-dependent cell death increasing the production of the clusterin pro-survival form (sCLU), finally shifting death into survival. In a moderately differentiated colon cancer cell line IL-6 down-modulated Bax expression at mRNA level. Concomitantly, IL-6 exposure influenced Bax at protein level acting on Bax-Ku70-sCLU physical interactions in the cytoplasm. In particular, it affected the acetylation and phosphorylation state of Ku70 [36]. The in vitro treatment with IL-6 and VEGF-A165 modulated the expression of genes involved in tumor invasion and apoptosis, as observed by microarray analysis [36]. In particular, microarray data showed that IL-6 could influence cell proliferation, not only by inducing AP1 formation, but also through the up regulation of RASp21 protein activator 1, myc and NFκB. On the other hand, IL-6 down-modulated the expression of genes involved in the inhibition of metastasis, such as TIMP1 metallopeptidase inhibitor 1 and KISS1 [40, 41]. These still unclear molecular interactions, underline the relevant role of the microenvironmental factors in the complicated cross talk among molecules that could effectively turn the cell fate, by a fine regulation of gene expression, also acting on miRNA expression.

Changes of the microenvironment mediators induced by hypoxia, represent an hallmark of cancer progression. In the tumoral context, the transcriptional regulator hypoxia-inducible factor (HIF1α), cooperates with IL-6, TGF-β and VEGF-A165 in the promotion of tumoral growth [10, 15, 17‐19].

The activation of hypoxia fosters neo-angiogenesis also regulating the expression of miR-210, and its target Ephrin-A3, involved in tube formation and survival of endothelial cells [42]. A group of candidate miRNAs regulated by hypoxia have been recently identified: miR-16, 20let-7b, miR-17-5p, miR-27, miR-106, miR-107 miR-193, miR-210, miR-320 and miR-361, showing VEGF as potential target [43, 73]. Moreover, using a bioinformatic prediction program, several key genes of proliferation, metabolism, migration and apoptotic response (miR-23, miR-26, miR-27, miR-30, miR-181) were found to be potentially targets of hypoxia-regulated miRNAs [57, 58]. In the colon cancer context, the synergism among hypoxic condition (HIF-1α activation) and IL-6 pro-inflammatory cytokine induces the up-regulation of VEGF-A165, contributing to neoangiogenesis and metastasis formation.

In colon cancer cells (Caco-2), we observed that the synergism of IL-6 and VEGF-A165 influenced the expression of tumor suppressor miRNAs, involved in epigenetic control and epithelial to mesenchymal transition (EMT), which strongly correlated to the malignization of many types of cancers [6]. In particular, the in vitro co-treatment with IL-6 and VEGF-A165 significantly down modulated miR-619, which targets VEGF gene expression determining a positive feed-back loop, finally contributing to cancer growth and spreading [44]. In addition, a significant decrease of miR-200 (12-folds decrease) was found, as compared to untreated colon cancer cells. The target prediction program indicates that highly conserved binding sites for the miRNA200 family are present in the ZEB1 and SIP1 mRNAs, which are repressors of ecadherin, implicated in EMT transition and tumor metastasis. The same down-regulation of miR-200 was obtained in response to TGF-β treatment and this effect was sufficient to induce EMT, in a process requiring up-regulation of ZEB1 and/or SIP1 [45]. In addition, Adam et al. [46] demonstrated that miR-200 controls the sensitivity to the EGFR therapy, which represents an actual issue in the treatment of human highly aggressive and metastatic colorectal cancer. In fact the expression of the miR-200 is sufficient to restore the EGFR dependency in bladder cancer cells, targeting ERRFI-1 which is a novel regulator of EGFR-independent growth.

In the last years, great attention has been given to the development of target anti-cancer therapies, based on the knowledge of transcriptional mechanisms epigenetically regulated in tumoral tissues. Moreover, it has been recently delineated a reciprocal interconnection between microRNAs and epigenetics [30]. The epigenetic modifications, such as DNA methylation or histone acetylation, are able to affect miRNAs expression causing oncomirs dysregulation, but the same microRNA (epi-miRNAs) may directly control the epigenetic machinery targeting its enzymatic components [30].

Evidence of the epigenetic influence of the microenvironment on tumoral cells has been observed by co-treating colon cancer cells with IL-6 and VEGF-A165. A strong down-modulation of the growth suppressing miR-449, which targets histone deacetylase 1 molecule (HDAC-1) [47] has been found in our system. This enzyme plays a crucial role in the epigenetic control and display high significance in oncology [48, 49]. Aberrant HDAC level and/or sustained activity has been found in various types of cancer and metastasis [50]. It has known that recruitment and activation of HDACs results in tightening of chromatin structure, thus the transcriptional machinery is prevented from accessing the DNA. Hence, cytokines and growth factors in the microenvironment could modulate gene transcription at epigenetic level, affecting epi-miRNA (as miR-449 [47]), or influencing the activity of protein involved in the regulation of HDAC activity (Fig. 1).

The altered metabolism of tumor cells may be a potential means by which these cells evade programmed cell death, favoring survival and tumoral growth. In particular, the metabolism of fatty acids is markedly altered in the tumoral context. It has been demonstrated that the extracellular acidosis in the microenvironment of solid tumors can work in an epigenetic fashion by up-regulating the transcriptional expression of fatty acids synthase (FASN) gene, proposed as the “metabolic oncogene” of cancer cells [51].

Recent reports demonstrated the existence of miRNAs able to recognize and modulate the transcriptional levels of metabolic factors, relevant both in non neoplastic and in cancer cell. In particular, transfection experiments with sense and antisense sequences displayed that the increase of lipogenesis in HepG2 cells (hepatocarcinoma cell line) is directly controlled by miR-122 [52]. This miRNA sequence is up-regulated by miR-370, the last therefore indirectly involved in the upregulation of lipogenic genes. Interestingly the same miR-370 targets the 3′UTR of CPT1, down-regulating the expression of CPT1A gene and the rate of β-oxidation [52].

Carnitine palmitoyl transferase 1 (CPT1) is another limiting factor in the fatty acids metabolism and it is contra-regulated by FASN substrate malonyl-CoA [53]. CPT1 resides physiologically at the mitochondrial membrane transporting long-chain fatty acids for β-oxidation. Recently, a CPT1A transcript splice variant, termed variant 2 (NM_001031847), was identified in colon cancer and breast cancer cells and it was undetectable in the corresponding non neoplastic cell line [53]. This variant codifies for a protein which differs in only 11 aminoacids from CPT1A variant 1, at the C-terminus. The preferential cellular localization of the two CPT1A variants was identified, being the product of transcript variant 2 mainly localized in the nucleus of tumoral cells.

The two transcript variants of CPT1A show great similarity differing only at the 3′-UTR level, where the recognition with miR-370 is located [52]. A different effectiveness of miR-370 in the target recognition could be responsible for the different levels of CPT1A transcripts found in cancer cell, as compared with non neoplastic cell. In fact, miR-370 could preferentially target CPT1 isoform 1 and indirectly favour CPT1 isoform 2, localized in the nucleus of cancer cells.

Experiments performed on human colorectal and breast tumoral tissues and cancer cell lines (Caco-2, HepG2 and MCF-7 cells) showed that the nuclear localization of CPT1A correlated to an increased HDAC activity and a resulting decrease of histone acetylation [53]. Moreover, HDAC-1 protein co-precipitated with CPT1A.

We have evidence of a different binding affinity of the two CPT1A variants for HDAC1. These data are based on the dissimilar CPT1 residues at the interface with HDAC1, for the two complexes. In the case of isoform 2 the interaction with HDAC1 involved a region close to the C-terminus, where the differences with CPT1 isoform 1 are located. Considering the great similarity of the other regions of CPT1 isoforms, this evidence suggested a higher stability of the complex CPT1 isoform2/HDAC1 (unpublished data). HDAC complexes are recruited to specific genomic sites by regulatory proteins. Additional data are needed to confirm if CPT1 (and in particular the nuclear isoform) could function as a novel partner of HDAC-1, stabilizing HDAC complexes at acetylated-histone tails of specific promoters, to silence tumor suppressor genes involved in the control of cancer cell growth and migration.

Experimental evidence suggest that, in tumoral context, the modulation of the metabolic factors could be driven by miRNA target recognition [52], but also through the activation of membrane receptors signalling, such as EGF/EGFR family, induced by microenvironmental stimuli [51, 54].

The human epidermal growth factor receptor type 1 (EGFR/HER-1) gene encodes a membrane receptor protein in the epidermal growth factor receptor family (ERBBs) and evidence suggests that EGFR expression and its activation status are associated with hyper-proliferation of colon cancer cells. Increased expression of EGFR is independently associated with poor disease-free survival after adjustment for stage, histological grade, age, and DNA mismatch repair status [55]. Epidermal growth factor and the EGF receptors (known as ERBB1) and ERBB2 have been shown to stimulate fatty acids synthase (FASN), the major enzyme required for the synthesis of fatty acids, although the ultimate mechanisms responsible for tumour-associated FASN overexpression are not completely understood. The effects of growth factors and growth factors receptors on FASN are complex and involve activation and/or cross-talk between multiple signal-transduction pathways [56] The EGFR activation found in colorectal cancer [55] could induce an up-regulation of FASN, determining the down-regulation of CPT1A activity in mitochondria [53].

Overall, in the neoplastic cells the gradient of microenvironmental factors (including EGF/EGFR activation) induces the overexpression of FASN and the resulting inhibition of fatty acids β-oxidation. Thus, a differential expression of CPT1A isoforms, driven by miRNA target recognition [52], could favour the CPT1 nuclear variant that evidence suggest to be implicated in the epigenetic regulation [53].

In conclusion, the metabolic factors altered in cancer could directly regulate the expression of genes implicated in tumor development and metastases, or modulate at epigenetic level the expression of small non coding RNAs. Besides, microRNAs have been identified (and many others remain to be uncovered) that target metabolic factors modulating their expression. Once more this regulatory loop seems to be driven by microenvironmental factors.